Zydus gets FDA nod for Ultracet painkiller

Shares touched a 52-week high on BSE at Rs 938 in intraday trade

Ahmedabad-based pharma major Cadila Healthcare (Zydus) has received the US drug regulator's nod to market a generic painkiller under the name Ultracet. The company's shares touched a 52-week high at the Bombay Stock Exchange (BSE) at Rs 938 in intra-day trade on Monday.

Cadila Healthcare's US subsidiary Zydus Pharma USA Inc received the US Food and Drug Administration's (USFDA) nod to market oral tablets of

Ultracet (Acetaminophen; Tradamadol hydrochloride) in the US in strengths of 325 mg and 37.5 mg, said a notice on the FDA website.

Sources in Zydus informed that global business accounts for nearly 50 per cent of its revenues, and US contributes a substantial portion. It is estimated that US operations contribute to over 25 per cent of the company's net sales.

Zydus' consolidated revenue figures touched Rs 5263.31 crore during the 2011-12 financial year, up from Rs 4630.59 crore in the previous fiscal.